To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 (GPC3) Targeted Chimeric Antigen Receptor T cell therapy in Patients with GPC3 Positive Advanced Hepatocellular Carcinoma who Have Failed Standard Therapy
Advanced Hepatocellular Carcinoma
BIOLOGICAL: EU307 CAR-T Cell
AEs (including DLT), In this study, DLT is defined as an AE related to the IP (EU307),and severity will be assessed according to NCI-CTCAE v5.0, up to 6 month from LPI|Production of replication competent lentiviruses (RCL), up to 6 month from LPI|Development of anti-drug antibodies (ADA), up to 6 month from LPI
ORR, Proportion of subjects with confirmed CR or partial response (PR) as best overall response (BOR), up to 6 month|DoR, Time from confirmed tumor response (CR or PR) to confirmed progressive disease (PD), up to 6 month|DCR, Proportion of subjects with confirmed CR, PR, or stable disease (SD) (â‰¥ 6 weeks) as BOR, up to 6 month|TTR, Time from IP dosing to confirmed objective response (CR or PR), up to 6 month|TTP, Time from IP dosing to PD, up to 6 month|PFS, Time from IP dosing to PD or all-cause death, whichever is earlier, up to 6 month|OS, Time from IP dosing to all-cause death, up to 6 month
Quantitative CAR-T DNA assay, up to 6 month|Immunological assessment, -To explore relationship to tumor response, parameters to be analyzed include, but are not limited to: IFN-g, TNF-a, IL-2, IL-6, IL-18, IL-10, RANTES, MCP-1, TGF--Analysis of T cells and immune cells, up to 6 month
A Dose-escalation, Single-arm, Open-Label, Phase 1 Study